Q1 2025 Oncolytics Biotech Inc Earnings Call Transcript
Key Points
- Oncolytics Biotech Inc (ONCY) reported promising clinical data for pelareorep, showing a 33% objective response rate in relapsed anal carcinoma, including a complete response lasting over 15 months.
- The company is actively enrolling patients in the GOBLET Cohort 5 study for metastatic pancreatic cancer, supported by a $5 million grant from the Pancreatic Cancer Action Network.
- Pelareorep demonstrated a favorable safety profile across multiple studies, allowing for combination with various chemotherapies and checkpoint inhibitors.
- The company has secured a USD20 million share purchase agreement with Alumni Capital, providing financial flexibility and extending the runway through key milestones.
- Oncolytics Biotech Inc (ONCY) is exploring multiple registrational opportunities for pelareorep in breast cancer, supported by positive data from two randomized Phase 2 studies showing significant clinical benefits.
- The company is still in the process of searching for a new CEO, which may impact strategic decision-making and leadership continuity.
- Despite promising data, regulatory approval for pelareorep in anal carcinoma is not guaranteed and the commercial opportunity is smaller compared to other indications.
- Research and development expenses decreased due to reduced manufacturing and clinical trial costs, which could indicate a slowdown in certain development activities.
- The net loss for the quarter was $6.7 million, reflecting ongoing financial challenges despite a slight improvement from the previous year.
- There have been no recent interactions with the FDA regarding the pancreatic cancer program, which could delay potential registrational pathways.
Good afternoon and welcome to Oncolytics Biotech's first-quarter conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would like to turn a call over to Jon Patton, Director of Investor Relations and Communication. Please go ahead.
Thank you, operator. Today we'll provide an update on the quarter and a review of our financials. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's ongoing CEO search, our mission, strategies, and milestones; the company's belief as to the potential and mechanism of action of pelareorep as a cancer therapeutic; our potential registrational opportunities for pelareorep and our plans and strategies related there too; our plans to continue enrollment in GOBLET Cohort 5; our ongoing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
